Reata Pharmaceuticals Inc (RETA) Insider Keith Wayne Ward Sells 4,750 Shares

Reata Pharmaceuticals Inc (NASDAQ:RETA) insider Keith Wayne Ward sold 4,750 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $66.97, for a total value of $318,107.50. Following the sale, the insider now directly owns 4,750 shares in the company, valued at approximately $318,107.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Keith Wayne Ward also recently made the following trade(s):

  • On Thursday, November 1st, Keith Wayne Ward sold 4,750 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $59.48, for a total value of $282,530.00.
  • On Tuesday, October 23rd, Keith Wayne Ward sold 14,250 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $57.08, for a total value of $813,390.00.

Shares of NASDAQ:RETA traded down $4.08 during trading on Friday, hitting $66.11. The stock had a trading volume of 9,347 shares, compared to its average volume of 242,520. Reata Pharmaceuticals Inc has a 12-month low of $19.31 and a 12-month high of $99.50. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -33.87 and a beta of 3.40.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.28). The firm had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $9.50 million. Research analysts expect that Reata Pharmaceuticals Inc will post -2.56 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on RETA shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $100.00 price objective on shares of Reata Pharmaceuticals in a research report on Monday, October 1st. BidaskClub downgraded Reata Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 28th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $133.00 price objective on shares of Reata Pharmaceuticals in a research report on Wednesday, September 26th. ValuEngine raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, July 18th. Finally, Zacks Investment Research raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research report on Friday, July 13th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $100.33.

Hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. purchased a new position in Reata Pharmaceuticals during the second quarter valued at approximately $6,962,000. Wallace Capital Management Inc. purchased a new position in Reata Pharmaceuticals during the second quarter valued at approximately $271,000. MetLife Investment Advisors LLC raised its position in Reata Pharmaceuticals by 72.7% during the second quarter. MetLife Investment Advisors LLC now owns 7,732 shares of the company’s stock valued at $270,000 after acquiring an additional 3,255 shares in the last quarter. First Manhattan Co. purchased a new position in Reata Pharmaceuticals during the second quarter valued at approximately $807,000. Finally, Sio Capital Management LLC purchased a new position in Reata Pharmaceuticals during the second quarter valued at approximately $1,533,000. Institutional investors own 40.73% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Reata Pharmaceuticals Inc (RETA) Insider Keith Wayne Ward Sells 4,750 Shares” was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.wkrb13.com/2018/11/09/reata-pharmaceuticals-inc-reta-insider-keith-wayne-ward-sells-4750-shares.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.

Recommended Story: Short Selling

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply